Showing 2341-2350 of 6036 results for "".
- CHOP Researchers Develop Highly Specific Predictive Screening Tool for Retinopathy in Premature Infantshttps://modernod.com/news/chop-researchers-develop-highly-specific-predictive-screening-tool-for-retinopathy-in-premature-infants/2480024/A multi-hospital collaboration led by researchers at Children’s Hospital of Philadelphia (CHOP) has found a simple method of determining which premature infants should be screened for retinopathy of prematurity (ROP). The recommendations have the potential t
- Ocular Therapeutix Announces NDA Resubmission of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-nda-resubmission-of-dextenza/2480054/Ocular Therapeutix has announced the resubmission of the company’s new drug application (NDA) to the FDA for its lead product candidate Dextenza (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing defic
- “Dr. Robert Ritch Forum on Medicine of the Future” at World Ophthalmology Congress 2018https://modernod.com/news/dr-robert-ritch-forum-on-medicine-of-the-future-at-world-ophthalmology-congress-2018/2480090/Robert Ritch, MD, Distinguished Chair in Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai will host the “Robert Ritch Forum on Medicine of the Future” at the World Ophthalmology Congress 2018 (WOC2018) in Barcelona, Spain. This is the first time WOC is dedicating an entire fo
- Takeda Reaches Deal to Buy Shire for $62 Billionhttps://modernod.com/news/takeda-reaches-deal-to-buy-shire-for-around-62-billion/2480166/After several failed attempts, Japanese drugmaker Takeda Pharmaceutical managed to reach an agreement to acquire Shire in a $62 billion deal. The offer is approximately 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combined group. Shire investors will
- J&J Vision Introduces Artificial-Intelligence Powered Virtual Assistant for Contact Lenseshttps://modernod.com/news/jj-vision-introduces-artificial-intelligence-powered-virtual-assistant-for-contact-lenses/2480195/Johnson & Johnson Vision introduced Andy, a virtual assistant chatbot powered by artificial intelligence (AI). Andy is designed to help guide U.S. consumers throughout their Acuvue brand contact lens journey – from those considering contact lenses for the first time to long-term wearers. The
- Blanchard Announces Notching Technology for the Onefit Family of Scleral Lenses: Control Peripheral Recesshttps://modernod.com/news/blanchard-announces-notching-technology-for-the-onefit-family-of-scleral-lenses-control-peripheral-recess/2480206/Blanchard Contact Lenses has unveiled their latest design option for its Onefit and Onefit MED scleral lenses. Control Peripheral Recess (CPR) is a manufacturing process that creates
- Bausch + Lomb Receives FDA 510(k) Clearance for Boston Scleral Lens Casehttps://modernod.com/news/bausch-lomb-receives-fda-510k-clearance-for-boston-scleral-lens-case/2480229/Bausch + Lomb announced that it has received 510(K) clearance from the FDA for the Boston scleral lens case, a storage case developed specifically for scleral lenses. The case is designed to hold lenses up to 23.5 millimeters in diameter and up to 10.0 millimeters in sagittal depth. The Boston sc
- Telemedicine Useful in Detecting Retinopathy of Prematurityhttps://modernod.com/news/telemedicine-useful-in-detecting-retinopathy-of-prematurity/2480230/Telemedicine has similar accuracy to ophthalmoscopy in detecting clinically significant retinopathy of prematurity (ROP), researchers say, according to a report in Reuters Health. “ROP is a leading cause of childhood blindness in the U.S. and throughout the world, yet it is often dif
- GlobalData: AI-Based Diabetic Retinopathy Device Can Reduce Burden on US Healthcare Systemhttps://modernod.com/news/globaldata-ai-based-diabetic-retinopathy-device-can-reduce-burden-on-us-healthcare-system/2480234/Iowa-based artificial intelligence (AI) diagnostics company IDx recently received market approval from the FDA for its AI-based medical device, IDx-DR, to detect greater than a mild level of diabetic retinopathy in adults. As the first of its kind to be authorized for commercialization, IDx-DR ha
- FDA Approves Marketing For First AI Device for Diabetic Retinopathy Detectionhttps://modernod.com/news/fda-permits-marketing-of-ai-based-device-to-detect-certain-diabetes-related-eye-problems/2480256/The FDA has permitted marketing for the first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. The device, called IDx-DR, is a software program that uses an artificial intelligence algorithm to analyze im